Wild-type (wt) p53 frequently induces apoptosis when expressed in tumor cells whereas mutant p53 acts as an oncoprotein and consequently, stimulates cell proliferation. We report here exceptions to that rule. p53 conformational mutant 175H and DNA contact mutant 273H provoke apoptosis in human p53-de®cient Hep3B hepatoma cells with delayed kinetics relative to wt p53. Similarly, c-Myc strongly stimulates apoptosis in these cells. In contrast, viral oncoproteins E1A and E7, and the cellular oncoprotein MDM-2, fail to elicit cytocidal responses. Ecient apoptotic cell death by mutant p53 requires oligomerization as 175H and 273H with deletions between amino acid residues 326 and 347 of the oligomerization domain are nontoxic. Apoptosis by mutant or wt p53 was signi®cantly inhibited by the serine protease inhibitor AEBSF but not by the inactive analog AEBSA. Together, these results suggest that a wt p53-independent control mechanism is operational in Hep3B cells that eliminates cells upon sensing illegitimate proliferation signals originating from certain oncoproteins, including mutant p53 and Myc. We suggest that some tumor cell types lack p53 altogether because they tolerate neither wild-type nor mutant forms of the protein.
Proper function of the multifunctional transcription factor p53 is critical for the prevention of neoplastic transformation in many cell types, and one important activity of p53 in this context seems to involve the elimination of damaged cells through apoptosis. There is no single function of p53 that alone regulates cell survival. Clearly, transactivation-dependent and -independent mechanisms have been identi®ed (see, for instance, Caelles et al., 1994; Haupt et al., 1995; Sabbatini et al., 1995) , with the transactivationdependent likely to be associated with the stimulation of apoptosis-promoting genes such as bax (Miyashita and Reed, 1995) , Fas/APO (Fuchs et al., 1997) , IGF-BP3 (Buckbinder et al., 1995) , PAG608 (Israeli et al., 1997) and the genes whose products damage mitochondria through reactive oxygen species (Polyak et al., 1997) . Other functions of p53 in apoptosis may involve the repression of certain genes that lack p53-responsive elements (Murphy et al., 1996; Polyak et al., 1997) .
Among the strongest indications for the action of transactivation-independent mechanisms during apoptosis-induction is the fact that elimination of a polyproline motif in p53's N-terminus leaves transactivation intact but compromises the mediation of cell death (Walker and Levine, 1996; Sakamuro et al., 1997) . Two consensi seem to be emerging from the many studies. First, apoptosis-induction appears to require relatively large quantities of p53 compared to the levels necessary for, for instance, the transactivation of CDKN1A (p21 WAF/Cip-1) (Chen et al., 1996) . Second, cell death by p53 seems to rely upon an intact core DNA binding domain . However, exceptions have been reported; p53 with a deletion reaching into the DNA-binding domain was toxic to HeLa cells (Haupt et al., 1995) , and low levels of p53 were found to be sucient to trigger death in cells that lack the atm gene (Barlow et al., 1997) . While some p53 mutants retain residual DNA binding/transactivation activity, it is generally recognized that mutant forms of p53, be it of the conformational or DNA contact type, are defective for the mediation of cell death (Ludwig et al., 1996; Friedlander et al., 1996) . We present here data indicating that some p53-negative cells types are nevertheless sensitive to apoptosis stimulated by mutant p53.
Initially we set out to develop cell lines from the human p53-de®cient Hep3B hepatoma line that express either the conformational p53 mutant 175H or the DNA contact mutant 273H. For this purpose, retroviruses were produced in 293GP cells and pseudotyped with the vesiculo stomatitis virus G protein to achieve high infectivity and a wide host range (Yee et al., 1994) , and were routinely titered on BHK cells ( Figure  1a ). These were not measurably aected in their survival by the expression of mutant p53. As expected, infection of BHK cells with either empty retroviral vector or vector containing one of the p53 mutants reproducibly resulted in the outgrowth of similar numbers of G418-resistant colonies. In contrast, infections of Hep3B cells with the mutant p53 vectors from the same virus stocks let to substantially fewer and smaller colonies than infections with empty retroviral vector (Figure 1b) . Furthermore, the Hep3B colonies infected with mutant p53 virus were more dicult to expand. Finally, when randomly picked colonies of drug-resistant Hep3B and BHK cells were analysed by immunoblotting for the production of p53, non-expressers were found among the Hep3B cell clones (Figure 1c ). These initial ®ndings indicated that, contrary to expectation, mutant p53 can confer a growth disadvantage to Hep3B cells.
Inspection of the Hep3B colonies suggested that the growth disadvantage was the result of cell loss. To further examine this, Hep3B cells were transiently co-transfected with 1 mg of an indicator plasmid expressing the bacterial b-galactosidase (lacZ) gene plus varying amounts of expression vectors producing either wild-type or mutant p53 driven by the strong CMV promoter/enhancer (Figure 1a ). The numbers of surviving lacZ-positive cells at dierent times upon transfection were determined and used as a measure for the toxicity of a construct, as previously described (Liu et al., 1996) . Figure 2a shows an example of the eects of 0.6 mg expression plasmids on the survival of Hep3B cells over a time course of 120 h. As expected and described earlier (Roemer and Mueller-Lantzsch, 1996) , wt p53 provoked massive cytopathic eects at early times after transfection, whereas empty expression vector was nontoxic over the entire time course. Remarkably, cells that had received mutant p53 plasmids were also disappearing from the cultures, although with delayed kinetics relative to the wild-type. To exclude the possibility that Hep3B cells are generally sensitive to the expression of oncoproteins, we transfected cultures with similar quantities of plasmids expressing viral E1A or E7, or the cellular MDM-2 oncoprotein from the strong CMV promoter. Immunoblot studies revealed that both E1A and MDM-2 were produced to high levels upon transfection (Figure 2d ). Expression of E7 was dicult to demonstrate in transient transfections because of the lack of useful antibodies; however, pCMV-E7 exhibited a strong proliferation-inducing capacity in colony formation assays, indicating that E7 like E1A and MDM-2 was expressed and functional. We observed that, in contrast to mutant p53, these oncoproteins were nontoxic to Hep3B cells ( Figure 2b ). We then went on to test the p53 variants in human Saos-2 osteosarcoma cells, another cell type de®cient for p53. In agreement with many previous studies, wt p53 was toxic to Saos-2 cells whereas 175H and 273H failed to show toxicity ( Figure 2b ).
Wt p53 can mediate apoptosis in Hep3B cells (Roemer and Mueller-Lantzsch, 1996) . We therefore analysed cells transfected with mutant p53 for hallmarks of apoptosis, that is, signs of nuclear fragmentation upon staining with DAPI, and the presence of DNA fragmentation in TUNEL assays (Theis et al., 1997) . While control-transfected cells showed no signs of apoptosis, many cells transfected with p53-175H or p53-273H attained a rounded morphology and were positive in both assays at 48 h after transfection ( Figure 2c and data not shown), demonstrating that mutant p53 can provoke apoptotic death in Hep3B cells. We next wished to determine what functional domains of the mutant p53 proteins are required to elicit this phenotype. To this end, expression vectors were constructed that produce either the full-length mutants 175H and 273H, or produce the same mutants that carry additional deletions at their N-terminus up to amino acid residue 79 or at their C-terminus within the oligomerization domain between amino acid residue 326 and 347 (see Figure 1a ). Immunoblot analysis demonstrated that all proteins were expressed to high levels upon transfection ( Figure 3a) . Cell death studies comprising these proteins revealed that oligomerization was essential for the ecient induction of cell death. For instance, while only approximately 50% of the cells transfected with mutant p53 survived and retained normal morphology at 72 h after transfection, 85 ± 95% of the cells that had received oligomerization-defective mutant p53 remained intact (Figure 3b ). We thus conclude that conformationaltered or DNA binding-defective mutant p53 with intact oligomerization domain can provoke programmed cell death in Hep3B cells with delayed kinetics relative to wt p53.
A more complex picture emerged when we tested for the function of the N-terminal domain of p53. The DNA contact variant 273H-DN was as toxic as fulllength 273H, whereas conformational mutant 175H-DN possessed a reduced cytotoxic potential when compared to 175H (Figure 3b ). The reasons for these dierences are unknown; however, the dierences correlate with variations in the cellular localization of the mutant proteins. While all 273H variants were Figure 1 (a) Dierent expression vectors used to produce p53 variants. Retroviral vectors were generated by insertion of the p53-175H or -273H sequences into the single BamHI site of the standard MoMLV-based LRNL vector that consists of a neo R -gene situated between two LTR elements and driven by the Roux sarcoma virus (RSV) promoter. The viruses were produced on the 293GP producer cell line and pseudotyped with VSV G protein as described (Yee et al., 1994) . Plasmid expression vectors were constructed by insertion of the indicated p53 genes into a single BamHI site downstream of a CMV promoter/enhancer of the empty vector pCMV-pA. Sequences termed -DO contain deletions within the oligomerization domain of human p53 between residues 326 and 347; constructs depicted as -DN lack the Nterminal 79 amino acid residues. (b) Numbers and sizes of Hep3B cell colonies at 31 days after infection with retroviral vectors. Exponentially growing cells in 10 cm dishes were exposed to 200 c.f.u. (titered on BHK cells) of either LRNL control vector (control), L175RNL (175H), or L273RNL (273H), and were selected in 800 mg/ml G418 for 28 days. (c) Hep3B and BHK cell clones infected with L175RNL were expanded and analysed for the expression of p53 by immunoblotting with antibody DO-1. Note that Hep3B clone 3 expresses signi®cantly less p53-175H, and that clone 4 fails to produce any detectable p53 strongly staining the cell nucleus, mutant 175H and its N-terminal deletion variant were predominantly cytoplasmic (data not shown). Thus, the mechanisms by which 175H and 273H activate apoptosis in Hep3B cells may be dierent and may involve the N-terminal 79 amino acid residues of the cytoplasmic 175H mutant but not of the nuclear 273H mutant.
Remarkably, while oncoproteins E1A, E7, and MDM-2 failed to provoke cytopathic eects (see Figure 2b ), c-Myc was as potent an inducer of Hep3B apoptosis as p53 (Figure 4a ). c-Myc can provoke cell death via p53-dependent and -independent pathways. Recent work has documented that one p53-dependent pathway involves the tumor necrosis factor receptor Figure 2 (a) Survival of transfected Hep3B cells over a time course of 120 h. Hep3B cultures in 35 mm dishes were transiently transfected with 1 mg of an indicator plasmid expressing lacZ plus 0.6 mg of either empty pCMV-pA vector (control) or plasmid producing one of the p53 variants. At the indicated time points, the cells were stained for lacZ and the numbers of transfected bluestaining cells with intact morphology on 20 random microscopic ®elds per dish (at 1006) were determined. Twenty ®elds on the control-transfected culture dishes contained a total of 150 ± 200 intact lacZ-positive cells. Small colonies (approx. four cells) that appeared at the later time points were counted as one surviving cell. Standard deviations were determined from a total of four experiments. (b) Hep3B and Saos-2 cultures were transfected as in (a), except that Hep3B cells received 0.6 mg of a pCMV-pA-based expression plasmid producing either E1A, E7, or MDM-2. Cell survival was monitored at 48 h (Hep3B) or 72 h (Saos-2) after transfection. (c) Hep3B cells on coverslips were transfected with 1 mg of pCMV-pA or a vector expressing either 175H or 273H. At 24 h after transfection, the cells were ®xated and assayed for the presence of nucleosomal DNA fragmentation by terminal transferase-mediated nick end-labelling (TUNEL). DNase I treated cells served as positive control. (d) Western immunoblot analysis of Hep3B cell extracts from cultures transfected with pCMV-pA vector expressing E1A or MDM-2. Twenty mg of total cellular protein was subjected PAGE; E1A was detected with monoclonal antibody M73 and MDM-2 was detected with monoclonal antibody SMP-1 (Santa Cruz) (TNFR) family of proteins (Klefstrom et al., 1997) . However, Hep3B cells do not contain functional p53 genes, nor do they express signi®cant levels of TNFR (MuÈ ller et al., 1997) . This suggests that death-signalling by c-Myc in Hep3B cells is mediated via a distinct pathway, one that may also be utilized by mutant p53. In accord with c-Myc's strong toxicity, we have not been able to detect any protein by immunoblot analysis, nor c-myc RNA by RT ± PCR in Hep3B cells (data not shown). With these observations in mind, we asked whether death of Hep3B cells by c-Myc or p53 can be inhibited by drugs that have been shown recently to block c-Myc-stimulated apoptosis in Rat-1 cells (Kagaya et al., 1997) . *See: Note added in proof.
We transfected lacZ indicator plasmid plus 0.6 mg of plasmids expressing either wt p53, 175H, 273H or cMyc and analysed for surviving cells at 48 h after transfection. Subsets of each transfection were treated with 0.2 mM 4-(2-aminoethyl)benzenesulfonyl¯uoride (AEBSF) or 0.2 mM 4-(2-aminoethyl)benzenesulfonamide (AEBSA). Caspases, the executing enzymes of almost all apoptotic pathways, are synthesized as proenzymes and activated through cleavage by serine proteases at the COOH sides of speci®c aspartate residues. AEBSF inhibits serine proteases through the sulfonylation of active site-serine residues without being signi®cantly toxic to cells at the used concentrations and incubation periods. AEBSA is an inactive AEBSF analog. Figure 4a and c show that AEBSF but not AEBSA was able to eciently inhibit the cell death induced by wt p53, mutant p53, and c-Myc. Experiments with cells that were transfected with 0.6 mg of expression plasmids and treated with varying concentrations of AEBSF or AEBSA for 48 h revealed that the inhibitory eect of AEBSF depended on the concentration of the drug. Inhibition of apoptosis was ®rst observable at 0.05 mM AEBSF and was maximal at approximately 0.2 mM; concentrations exceeding 0.2 mM AEBSF caused detectable toxicity to the nontransfected cells in culture (Figure 4b ). Since apoptosis by wt p53 may involve caspase 3 (Chandler et al., 1997) , we incubated transfected cells with the caspase 3 inhibitor DEVD-FMK (Clontech). However, even at a concentration in the medium of 1 mM we were not able to block apoptosis induced by any of the proteins, which may be the result of inecient uptake of this substance (Kagaya et al., 1997) . Furthermore, we failed to detect any cleavage of the colorimetric substrate of caspase 3, DEVD-pNA (Clontech), in extracts from transiently transfected cultures. Thus, the determination of the caspase(s) involved in Hep3B cell death by p53 and c-Myc requires further study. In summary, we conclude that mutant p53 can stimulate apoptosis in Hep3B cells when oligomerization-competent, and that this cell death, like apoptosis by c-Myc, depends upon functional serine proteases.
Wild-type p53 kills tumor cells via transactivationdependent and -independent mechanisms. Precisely what mechanisms are operational seems to be a function of the cell type or even sub-cell line under study. For instance, E1A-producing BRK cells die in the presence of transactivation-competent p53 but not transactivation domain mutant p53-22,23 (Sabbatini et al., 1995) . In these cells, the expression of the p53-responsive bax gene is sucient to trigger apoptosis. In other cell types, p53 transactivates redox-related genes whose products support the formation of reactive oxigen species and thereby trigger apoptosis (Polyak et al., 1997) . Hep3B cell sublines either undergo apoptosis eciently only by a p53 capable of transactivating genes (Roemer and Mueller-Lantzsch, 1996) , or are resistant to p53-mediated cell death altogether (Friedman et al., 1997) . Immortalized B cells in G1/S phase of cell cycle and some HeLa cell sublines require transactivation-intact p53 to undergo apoptosis (Allday et al., 1995; Yonish-Rouach et al., 1995) . In contrast, other HeLa cells and also Saos-2 osteosarcoma cells can be eliminated by the expression of a DNA binding-defective p53 variant (Haupt et al., 1995) . Finally, mouse somatotropic GHFT1 cells die of p53-mediated apoptosis in the presence of transcriptional and translational inhibitors (Caelles et al., 1994) . Figure 1a ). Twenty mg of total cellular protein was subjected PAGE and p53 was detected with antibody DO-1 at a concentration of 0.2 mg/ml; the N-terminal deleted mutants and wt p53 as control were stained with PAb122 at 0.5 mg/ml. (b) Hep3B cultures were transiently transfected as in Figure 2a , with 1 mg of the lacZ indicator plasmid and 0.6 mg of either control pCMV-pA plasmid or vector expressing a p53 mutant or its N-or C-terminal deleted form. The numbers of surviving intact cells that stained positive for lacZ were determined at 72 h after transfection It is generally observed that tumor-associated mutant forms of p53 such as the DNA contact mutant 273H or the conformational mutant 175H are defective for the induction of cell death. This seems to hold true even for those tumor-derived mutants that retain limited DNA binding and transactivating functions or even a limited capability to induce G1 arrest. For instance, human p53-175P or -143A can stimulate the expression of target genes that are particularly sensitive to transactivation by p53 such as CDKN1A, but fail to induce programmed cell death in cell types in which apoptosis by p53 requires transactivation (Ludwig et al., 1996; Friedlander et al., 1996) . This has been suggested to re¯ect the lower binding anities of p53 for the promoters of the p53-responsive apoptosis-promoting genes (Friedlander et al., 1996) . Together, the defectiveness of p53 mutants for the ecient induction of cell death seems to re¯ect the necessity, in almost all experimental cell systems and regardless of the involvement of transactivation, of a fully functional core DNA binding domain for this function. We have shown here that, contrary to expectation, p53-175H and -273H can stimulate a delayed apoptotic response relative to wt p53 in p53-de®cient Hep3B cells, whereas other oncoproteins such as E1A, E7, or MDM-2 fail to do so. Does this suggest that these mutants retain wt p53-functions in this cell type? We were unable to ®nd such functions; for instance, we failed to observe transactivation of reporter genes by mutant p53 in Hep3B cells ( Figure  4d ). We therefore suggest that oncogenic mutant p53 triggers a cell death mechanism in Hep3B cells that is distinct from the one induced by wt p53. Previous ®ndings have indicated that illegitimate proliferation signals by oncoproteins may be sensed by a control system that involves wt p53 (for instance, Debbas and White, 1993) . Our results, in contrast, hint at a system that controls cell survival and senses mutant p53 (and c-Myc) but functions independently of wt p53. This control system is triggered eciently only by oligomerization-competent mutant p53, and it is precisely the oligomerization-competent mutants that are oncogenic. Oncoprotein-induced apoptosis in the absence of functional wt p53 has been reported in the past. For Figure 2a , with lacZ indicator plasmid plus an expression vector producing one of the p53 variants or c-Myc. At the time of medium change, at 7 h after transfection, the new medium was either mock-treated (7) or complemented with 0.2 mM of the serine protease inhibitor 4-(2-aminoethyl)benzenesufonyl-¯uoride (AEBSF) or 0.2 mM of the inactive analog 4-(2-aminoethyl)benzenesulfonamide (AEBSA) (Wako Chemical Industries, Japan). The numbers of surviving transfected cells were determined at 48 h after transfection. (b) The protective eect of AEBSF is concentration-dependent. Hep3B cultures transfected with expression plasmids producing a p53 protein or c-Myc were exposed to AEBSF or AEBSA as in (a), with the ®nal concentrations of the drugs varying between 0 and 0.4 mM. The numbers of intact blue-staining cells on 10 random microscopic ®elds are plotted. Note that 0.05 mM of AEBSF were sucient to elicit a signi®cant protective eect against the cell death provoked by all tested proteins, and that 0.2 mM were maximally protective. Cytotoxicity of AEBSF became apparent at concentrations above 0.2 mM and incubation periods above 40 h. (c) Morphology of transfected Hep3B cells in the presence or absence of AEBSF. Control-transfected lacZ-positive cells showed an intact morphology at 48 h after transfection (white arrowheads), whereas p53-transfected cells appeared shrunken and rounded-up in the absence of AEBSF (dark arrows). Serine protease inhibitor AEBSF but not AEBSA at 0.2 mM overcame this phenotype (white arrowhead). (d) Mutants 175H and 273H are nonfunctional as transactivators in Hep3B cells. Cells on 35 mm dishes were transfected with 4 mg of a reporter plasmid carrying p53 recognition motifs upstream of a CAT gene (PG13-CAT) plus 0.01 mg of empty vector or vector expressing one of the p53 proteins. CAT activity was determined at 48 h after transfection through a non-chromatographic CAT assay (Theis et al., 1997) instance, oncogenic Ras and E1A can induce apoptosis in p53-negative cells upon inhibition of the protective function of NFkB transcription factor (Mayo et al., 1997) . We interpret our observations to suggest that some tumor cell types lack p53 altogether because they tolerate neither wild-type nor mutant forms of the protein.
Note added in proof Frazier et al. ((1998) . Mol. Cell. Biol., 18, 3735 ± 3743) have reported recently that the c-myc gene can be transactivated by mutant p53.
